Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Zvi Steinberg who wrote (1425)	10/15/1998 1:31:00 PM
From: yosi s	of 1491

Earth to pars investor Earth to pars investors. All those that are discussing oral form other indication are way ahead of themselves. If you want to prove that HU211 is effective in preventing mild injury. You need big numbers lots of money and some more time. Ie, it will take at a lot longer than 6 month and a lot more that 1000 patients. Now if and when HU211 is proven effective and it is on the market and producing revenues and PARS got a percentage of it cash flow for on going study then it is worthwhile. To gie an example we got a baby in diapers and you are allready got college and weddin plans. All in good times. Pharmos got a great product in HU 211. and it is under valued, in my opinion, at these levels. With 2 product on market with potential to expand market. Europe, with near potential of getting Le Tobra, and HU 211. Yosi

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next